The phrase "a significantly higher affinity" is correct and usable in written English.
It can be used in contexts where you are comparing the strength of attraction or binding between two entities, such as molecules or receptors.
Example: "The new drug demonstrated a significantly higher affinity for the target receptor compared to the previous version."
Alternatives: "a notably greater affinity" or "a markedly higher affinity".
Complementary target DNA hybridization was shown to have a significantly higher affinity constant (KA) than MM1 and MM2.
Mannotriose and mannopentaose do not exhibit a significantly higher affinity than their linear moiety Manα1,3Man (Kd∼200 nM).
These demonstrated that Vg possesses a significantly higher affinity to the microbial surface molecules rather than BSA and the self components from H. otakii itself.
Among the aromatic moieties, tryptophan was ranked as the residue with highest amyloidogenic potential by Dobson and co-workers [26] and an un-biased analysis, using peptide array technology, has clearly indicated a significantly higher affinity of tryptophan-modified recognition module in the molecular association of the islet amyloid polypeptide [27].
For example, genistein has a significantly higher affinity for ERs than biochanin A [ 29, 30].
All the peptides showed a significantly higher affinity for HS than for CS (Table 5).
Thus, we found a significantly high affinity of OsSMF1 for the ACGT motif, CCACGT(G/C), which may be considered an OsSMF1-specific binding motif (Fig. 2).
G6-31 is a next generation synthetic monoclonal antibody derived from a phage library that inhibits murine and human VEGF-A with significantly higher affinity than bevacizumab.
Differences in this region may also play a role in the significantly higher affinity of PK11195 reported for human and for rat TSPO expressed in R. sphaeroides compared to the endogenous RsTSPO.
12 This electrochemical biosensor used a hairpin aptamer that showed significantly higher affinity for IFN-γ compared to linear aptamer described here (hairpin Kd 0.3 nM, linear aptamer Kd 3 nM determined by SPR).
It acts as a decoy receptor irreversibly binding to circulating VEGF-A, VEGF-B, and placental growth factors with significantly higher affinity than bevacizumab.
